The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | qIP-MS in high-risk myeloma patients in the GEM-CESAR trial
Noemí Puig, MD, PhD, University Hospital Salamanca, Salamanca, Spain, discusses the use of quantitative immunoprecipitation mass spectrometry (QIP-MS) as a measure of minimal residual disease (MRD) in high-risk smoldering myeloma patients enrolled in the GEM-CESAR study (NCT02415413). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
